Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid

Int J Dermatol. 2018 Nov;57(11):1372-1374. doi: 10.1111/ijd.13970. Epub 2018 Apr 6.

Authors

Alyson V Ridpath¹, Polina V Rzepka², Sabrina M Shearer², Scott R Scrape³, Thomas E Olencki⁴, Benjamin H Kaffenberger²

Affiliations

¹ Dermatology, Ohio Health, Athens, Ohio, USA.
² Department of Internal Medicine, Division of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
³ Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
⁴ Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

PMID: 29624655
DOI: 10.1111/ijd.13970

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Combined Modality Therapy
Humans
Male
Melanoma / drug therapy*
Nivolumab / adverse effects
Pemphigoid, Bullous / chemically induced*
Pemphigoid, Bullous / therapy*
Plasma Exchange*
Rituximab / therapeutic use*
Skin Neoplasms / drug therapy*

Substances

Antineoplastic Agents, Immunological
Nivolumab
Rituximab